Opinion on Biotechnology

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A battle looms in mild cognitive impairment...

More than a tenth of the world's elderly people have mild cognitive impairment, representing a significant potential market. Worse, these sufferers have a 50% chance developing Alzheimer's. Although there is no approved treatment available yet, several different therapies are in development. The fight for dominance in this potentially lucrative market is about to begin - but who will win out?

Published By Datamonitor
07 Dec 2001
Expert View
Expert View

A European home for orphan drugs

Published By Datamonitor
15 Feb 2001
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor
09 Apr 2001
CommentWire
CommentWire

Abbott/Millennium: a strong alliance

Published By Datamonitor
14 Mar 2001
CommentWire
CommentWire

Abbott/Millennium: genomics partnership advances

Obesity is a serious public health concern, costing over $100 billion a year in the US alone, and MLN4760 will complement Abbott's metabolic disease program well. It is also the first fruit of a strategic alliance to develop drugs based on genomic research. Such alliances will become increasingly important in the industry over the next few years.

Published By Datamonitor
28 Nov 2001
CommentWire
CommentWire

Abgenix/Amgen: colon cancer drug could challenge Erbitux

Abgenix and Amgen plan to submit an application to market colon cancer drug panitumumab by the end of 2005 after US regulators awarded the drug fast track status. With this indication already dominated by Genentech's Avastin and ImClone's Erbitux, panitumumab will need to demonstrate a survival advantage in phase III testing in order to establish itself in the colon cancer drug market.

Published By Datamonitor
03 Aug 2005
CommentWire
CommentWire

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor
07 Jan 2002
Expert View
Expert View

Acute respiratory distress syndrome: searching for effective therapies

Acute respiratory distress syndrome has an annual incidence of up to 75 cases per 100,000 in the US. The condition remains very difficult to treat with a mortality rate between 30% and 60%. Although much research into ARDS has been carried out, the lack of a standard definition for the condition has made trial results unclear, so what hope is there of a treatment breakthrough in the near future?

Published By Datamonitor
23 Aug 2002
CommentWire
CommentWire

Adolor: no pain, large gains

Published By Datamonitor
21 Dec 2000

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.